New modality of nucleic acid medicine, antibody-nucleic acid conjugates

Authors

Yoshitaka Shirasago
Tsukasa Sugo (ORCID: https://orcid.org/0000-0003-1834-2204)

Institutions

Genocea (United States) (US)

Publication Details

Journal: Drug Delivery System
Published: 2025-11-25
DOI: https://doi.org/10.2745/dds.40.393
Primary Topic: HER2/EGFR in Cancer Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

New modality of nucleic acid medicine, antibody-nucleic acid conjugates

Yoshitaka Shirasago, Tsukasa Sugo

Nov 25, 2025

Drug Delivery System

HER2/EGFR in Cancer Research

article

New modality of nucleic acid medicine, antibody-nucleic acid conjugates

Yoshitaka Shirasago, Tsukasa Sugo

November 25, 2025article en

Abstract

No abstract available for this paper.

Drug Delivery SystemVol. 40(5)

Genocea (United States) (US)

Zero hunger

Openalex Percentile: Top 27%

HER2/EGFR in Cancer Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

New modality of nucleic acid medicine, antibody-nucleic acid conjugates — Yoshitaka Shirasago, Tsukasa Sugo · Drug Delivery System (2025) | TGRS Research Map | TGRS